{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:46:22Z","timestamp":1791215182604,"version":"4.1.0"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Introduction<\/jats:title><jats:p>More than 70% of new HIV infections in Asia occurred in eight countries in 2020: Cambodia, China, India, Indonesia, Myanmar, Nepal, Thailand, and Vietnam\u2014with a rising incidence among men who have sex with men (MSM). The World Health Organization (WHO) recommends pre-exposure prophylaxis (PrEP) for those at risk of acquiring HIV, yet wide-scale implementation of PrEP, on a daily or event-driven basis, has been limited in Asia.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>The Optima HIV model was applied to examine the impact of scaling-up PrEP over five-years to cover an additional 15% of MSM compared with baseline coverage, a target deemed feasible by regional experts. Based on behavioral survey data, we assume that covering 15% of higher-risk MSM will cover 30% of all sexual acts in this group. Scenarios to compare the impact of generic-brand daily dosing of PrEP with generic event-driven dosing (15 days a month) were modelled from the start of 2022 to the end of 2026. Cost-effectiveness of generic versus branded PrEP was also assessed for China, the only country with an active patent for branded, higher cost PrEP. The impact on new HIV infections among the entire population and cost per HIV-related disability-adjusted life year (DALY) averted were estimated from the beginning of 2022 to the end of 2031 and from 2022 to 2051.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>If PrEP were scaled-up to cover an additional 15% of MSM engaging in higher-risk behavior from the beginning of 2022 to the end of 2026 in the eight Asian countries considered, an additional 100,000 (66,000\u2013130,000) HIV infections (17%) and 300,000 (198,000\u2013390,000) HIV-related DALYs (3%) could be averted over the 2022 to 2031 period. The estimated cost per HIV-related DALY averted from 2022 to 2031 ranged from US$600 for event-driven generic PrEP in Indonesia to US$34,400 for daily branded PrEP in Thailand. Over a longer timeframe from 2022 to 2051, the cost per HIV-related DALY averted could be reduced to US$100\u2013US$12,700.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusion<\/jats:title><jats:p>PrEP is a critical tool to further reduce HIV incidence in highly concentrated epidemics. Implementing PrEP in Asia may be cost-effective in settings with increasing HIV prevalence among MSM and if PrEP drug costs can be reduced, PrEP could be more cost-effective over longer timeframes.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0268240","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T17:30:05Z","timestamp":1653586205000},"page":"e0268240","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling study"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5938-6970","authenticated-orcid":true,"given":"Debra C.","family":"ten Brink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Martin-Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1517-3476","authenticated-orcid":true,"given":"Mark E.","family":"Minnery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron J.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather-Marie A.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly E.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshmie","family":"Ramaurtarsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"pone.0268240.ref001","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach Geneva: World Health Organization; 2016. [https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/208825\/9789241549684_eng.pdf?sequence=1]."},{"key":"pone.0268240.ref002","unstructured":"UNAIDS. UNAIDS Data 2021 Report. Geneva: UNAIDS; 2021. [https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/JC3032_AIDS_Data_book_2021_En.pdf]."},{"key":"pone.0268240.ref003","unstructured":"National AIDS Control Organisation I-NIoMS. India HIV Estimates 2019: Report. New Delhi; 2020. [http:\/\/naco.gov.in\/sites\/default\/files\/Estimation%20Report%202019.pdf]."},{"key":"pone.0268240.ref004","unstructured":"National Health and Family Planning Commission of the People\u2019s Republic of China. 2015 China AIDS Response Progress Report. 2015. [https:\/\/www.unaids.org\/sites\/default\/files\/country\/documents\/CHN_narrative_report_2015.pdf]."},{"key":"pone.0268240.ref005","unstructured":"UNAIDS. UNAIDS Global 2020 Report. Geneva: UNAIDS; 2020. [https:\/\/aids2020.unaids.org\/report\/]."},{"key":"pone.0268240.ref006","unstructured":"UNAIDS. Miles to go: global AIDS update 2018. Geneva, Switzerland; 2018. [https:\/\/www.unaids.org\/en\/resources\/documents\/2018\/global-aids-update]."},{"issue":"6","key":"pone.0268240.ref007","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1071\/SH18065","article-title":"Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand","volume":"15","author":"N Phanuphak","year":"2018","journal-title":"Sex Health"},{"key":"pone.0268240.ref008","volume-title":"AIDS","author":"BN Vu","year":"2018"},{"key":"pone.0268240.ref009","unstructured":"Ministry of Health NCfHA, Dermatology and STD,. Concept-note on HIV Pre-Exposure Prophylaxis (PrEP) Implementation in Cambodia. 2019. [https:\/\/niph.org.kh\/niph\/uploads\/library\/pdf\/GL199_PrEP_concept_note-EN.pdf]."},{"key":"pone.0268240.ref010","unstructured":"A multicenter, real-world study on two oral Truvada approaches to prevent HIV infection among MSM in China (CROPrEP) [press release]."},{"key":"pone.0268240.ref011","unstructured":"AVAC. Global PrEP Watch February 2019 [https:\/\/www.prepwatch.org\/resource\/global-prep-tracker\/]."},{"issue":"3","key":"pone.0268240.ref012","doi-asserted-by":"crossref","first-page":"a007419","DOI":"10.1101\/cshperspect.a007419","article-title":"HIV prevention by oral preexposure prophylaxis","volume":"2","author":"W Heneine","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"pone.0268240.ref013","unstructured":"Appropriate Medicines: Options for Pre-Exposure Prophylaxis. Geneva: World Health Organization; 2018. [https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273934\/WHO-CDS-HIV-18.22-eng.pdf]."},{"key":"pone.0268240.ref014","unstructured":"World Health Organization. What\u2019s the 2+1+1? Geneva, Switzerland; 2019. [https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325955\/WHO-CDS-HIV-19.8-eng.pdf?ua=1]."},{"key":"pone.0268240.ref015","article-title":"Incidence of HIV-infection with daily or on demand oral PrEP with TDF\/FTC in France","author":"J-M Molina","journal-title":"CROI"},{"issue":"16","key":"pone.0268240.ref016","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1097\/QAD.0000000000001627","article-title":"Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries","volume":"31","author":"E Hoornenborg","year":"2017","journal-title":"AIDS"},{"issue":"Suppl 5","key":"pone.0268240.ref017","doi-asserted-by":"crossref","first-page":"e25129","DOI":"10.1002\/jia2.25129","article-title":"Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand","volume":"21","author":"C Suraratdecha","year":"2018","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"pone.0268240.ref018","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10461-018-2205-3","article-title":"Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China","volume":"23","author":"L Zhang","year":"2019","journal-title":"AIDS Behav"},{"issue":"7","key":"pone.0268240.ref019","first-page":"1800398","article-title":"Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058","volume":"24","author":"DAMC van de Vijver","year":"2019","journal-title":"Euro Surveill"},{"issue":"1","key":"pone.0268240.ref020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/QAD.0000000000001658","article-title":"Costs and benefits of on-demand HIV preexposure prophylaxis in MSM","volume":"32","author":"I Durand-Zaleski","year":"2018","journal-title":"AIDS"},{"issue":"3","key":"pone.0268240.ref021","doi-asserted-by":"crossref","first-page":"e1001401","DOI":"10.1371\/journal.pmed.1001401","article-title":"The Cost and Impact of Scaling Up Pre-exposure Prophylaxis for HIV Prevention: A Systematic Review of Cost-Effectiveness Modelling Studies","volume":"10","author":"GB Gomez","year":"2013","journal-title":"PLOS Medicine"},{"key":"pone.0268240.ref022","unstructured":"M\u00e9decins sans Fronti\u00e8res. Untangling The Web of Antiretroviral Price Reductions. Geneva, Switzerland; 2020. [https:\/\/msfaccess.org\/sites\/default\/files\/2020-11\/HIV_Brief_Untangling-the-Web_2020.pdf]."},{"issue":"3","key":"pone.0268240.ref023","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/QAD.0b013e32835ca2dd","article-title":"The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis","volume":"27","author":"I Cremin","year":"2013","journal-title":"AIDS"},{"key":"pone.0268240.ref024","unstructured":"Gannon S, Herrick T, Green D, Green K, Thanh Nguyen H, Cummings R, et al. PrEP for key populations in Hanoi and Ho Chi Minh City, Vietnam has the potential to cost-effectively decrease HIV incidence in urban settings: a mathematical modeling analysis AIDS 20182018."},{"issue":"1","key":"pone.0268240.ref025","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/s12879-018-3516-8","article-title":"A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China","volume":"18","author":"J Li","journal-title":"BMC Infectious Diseases"},{"issue":"4","key":"pone.0268240.ref026","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/cid\/ciz249","article-title":"The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India","volume":"70","author":"P Kazemian","year":"2019","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"pone.0268240.ref027","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/QAI.0000000000000605","article-title":"Optima: a model for HIV epidemic analysis, program prioritization, and resource optimization","volume":"69","author":"CC Kerr","year":"2015","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"4","key":"pone.0268240.ref028","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3018(18)30024-9","article-title":"The global Optima HIV allocative efficiency model: targeting resources in efforts to end AIDS","volume":"5","author":"SL Kelly","year":"2018","journal-title":"Lancet HIV"},{"issue":"8","key":"pone.0268240.ref029","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jval.2016.04.015","article-title":"The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought","volume":"19","author":"T Wilkinson","year":"2016","journal-title":"Value in Health"},{"issue":"23","key":"pone.0268240.ref030","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection","volume":"373","author":"JM Molina","year":"2015","journal-title":"N Engl J Med"},{"issue":"10013","key":"pone.0268240.ref031","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"S McCormack","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"151","key":"pone.0268240.ref032","doi-asserted-by":"crossref","first-page":"151ra25","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"PL Anderson","year":"2012","journal-title":"Sci Transl Med"},{"issue":"5","key":"pone.0268240.ref033","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1521\/aeap.2019.31.5.452","article-title":"Pre-Exposure Prophylaxis (PrEP) Use is Associated With Health Risk Behaviors Among Moderate- and Heavy-Drinking MSM","volume":"31","author":"P Luehring-Jones","year":"2019","journal-title":"AIDS Educ Prev"},{"key":"pone.0268240.ref034","unstructured":"National team Cambodia U, Optima Consortium for Decision Science,. Ending the AIDS epidemic in Cambodia. 2020. [http:\/\/optimamodel.com\/pubs\/Cambodia_HIV_2020.pdf]."},{"issue":"5","key":"pone.0268240.ref035","doi-asserted-by":"crossref","first-page":"e0216774","DOI":"10.1371\/journal.pone.0216774","article-title":"The cost of HIV services at health facilities in Cambodia","volume":"14","author":"K Thin","year":"2019","journal-title":"PLOS ONE"},{"issue":"1","key":"pone.0268240.ref036","doi-asserted-by":"crossref","first-page":"e0170773","DOI":"10.1371\/journal.pone.0170773","article-title":"Costing of National STI Program Implementation for the Global STI Control Strategy for the Health Sector, 2016\u20132021","volume":"12","author":"EL Korenromp","year":"2017","journal-title":"PLOS ONE"},{"key":"pone.0268240.ref037","unstructured":"World Health Organization. Global Price Reporting Mechanism Geneva: WHO; [http:\/\/apps.who.int\/hiv\/amds\/price\/hdd\/]."},{"key":"pone.0268240.ref038","unstructured":"World Health Organization. Country-specific inpatient and outpatient estimates in 2010 currency Geneva: WHO-CHOICE; [https:\/\/www.who.int\/choice\/cost-effectiveness\/inputs\/health_service\/en\/]."},{"key":"pone.0268240.ref039","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/s12913-015-1098-3","article-title":"Costs of HIV\/AIDS treatment in Indonesia by time of treatment and stage of disease","volume":"15","author":"AYM Siregar","year":"2015","journal-title":"BMC health services research"},{"key":"pone.0268240.ref040","unstructured":"Government of Nepal MoH, National Centre for AIDS and STD Control Country Progress Report Nepal. 2017. [https:\/\/www.unaids.org\/sites\/default\/files\/country\/documents\/NPL_2018_countryreport.pdf]."},{"issue":"1","key":"pone.0268240.ref041","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/QAI.0b013e3182a17d15","article-title":"Costing analysis of national HIV treatment and care program in Vietnam","volume":"65","author":"AT Duong","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0268240.ref042","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2016 (GBD 2016) Disability Weights. Seattle; 2017.]."},{"issue":"10100","key":"pone.0268240.ref043","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0140-6736(17)31833-0","article-title":"Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"H Wang","year":"2017","journal-title":"The Lancet"},{"key":"pone.0268240.ref044","volume-title":"The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review","author":"J Kazibwe","year":"2021"},{"issue":"12","key":"pone.0268240.ref045","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost\u2013effectiveness thresholds: pros and cons","volume":"94","author":"MY Bertram","year":"2016","journal-title":"B World Health Organ"},{"issue":"6","key":"pone.0268240.ref046","doi-asserted-by":"crossref","first-page":"e000964","DOI":"10.1136\/bmjgh-2018-000964","article-title":"Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data","volume":"3","author":"J Ochalek","year":"2018","journal-title":"BMJ Global Health"},{"issue":"8","key":"pone.0268240.ref047","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","article-title":"Country-level cost-effectiveness thresholds: initial estimates and the need for further research","volume":"19","author":"B Woods","year":"2016","journal-title":"Value in Health"},{"key":"pone.0268240.ref048","unstructured":"The World Bank Group. GDP per capita (current US$) 2021 [https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD]."},{"issue":"1","key":"pone.0268240.ref049","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12889-020-08488-w","article-title":"Low willingness to pay for pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in China","volume":"20","author":"W Cao","year":"2020","journal-title":"BMC Public Health"},{"issue":"1","key":"pone.0268240.ref050","doi-asserted-by":"crossref","first-page":"21885","DOI":"10.7448\/IAS.20.1.21885","article-title":"Willingness to use HIV pre-exposure prophylaxis among gay men, other men who have sex with men and transgender women in Myanmar","volume":"20","author":"BL Draper","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"pone.0268240.ref051","unstructured":"World Health Organization. Pre-exposure prophylaxis services in Thailand during COVID-19 2020 [https:\/\/www.who.int\/news\/item\/26-11-2020-pre-exposure-prophylaxis-services-in-thailand-during-covid-19]."},{"issue":"2","key":"pone.0268240.ref052","doi-asserted-by":"crossref","first-page":"e12451","DOI":"10.2196\/12451","article-title":"Estimation of the Population Size of Men Who Have Sex With Men in Vietnam: Social App Multiplier Method","volume":"5","author":"VH Son","year":"2019","journal-title":"JMIR Public Health Surveill"},{"issue":"1","key":"pone.0268240.ref053","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.2196\/publichealth.9321","article-title":"Population Size Estimation of Gay and Bisexual Men and Other Men Who Have Sex With Men Using Social Media-Based Platforms","volume":"4","author":"S Baral","year":"2018","journal-title":"JMIR Public Health Surveill"},{"key":"pone.0268240.ref054","article-title":"Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis (PrEP) in HIV epidemics in sub-Saharan Africa: a modelling study","author":"A Phillips","year":"2022","journal-title":"The Lancet HIV"},{"issue":"7","key":"pone.0268240.ref055","doi-asserted-by":"crossref","first-page":"e25531","DOI":"10.1002\/jia2.25531","article-title":"A review of HIV pre-exposure prophylaxis (PrEP) programmes by delivery models in the Asia-Pacific through the healthcare accessibility framework","volume":"23","author":"JYC Lau","year":"2020","journal-title":"Journal of the International AIDS Society"},{"issue":"5","key":"pone.0268240.ref056","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s10461-016-1627-z","article-title":"Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature","volume":"21","author":"FM Koechlin","year":"2017","journal-title":"AIDS Behav"},{"issue":"1","key":"pone.0268240.ref057","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1071\/SH20172","article-title":"Demedicalisation of HIV interventions to end HIV in the Asia-Pacific","volume":"18","author":"R Janamnuaysook","year":"2021","journal-title":"Sex Health"},{"issue":"7","key":"pone.0268240.ref058","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women","volume":"385","author":"RJ Landovitz","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"pone.0268240.ref059","unstructured":"ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women [press release]. 2020."},{"key":"pone.0268240.ref060","unstructured":"UNAIDS. Prevailing against pandemics: by putting people at the centre. 2020. [https:\/\/aidstargets2025.unaids.org\/assets\/images\/prevailing-against-pandemics_en.pdf]."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0268240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T07:35:01Z","timestamp":1700638501000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0268240"}},"subtitle":[],"editor":[{"given":"Hamid","family":"Sharifi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0268240","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]}}}